Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sean F Hackett

Showing results (41-50 of 49) with videos related to

Pageof 5
Sort By:
You have reached the last page of results.This site can display upto 49 results.
Developmental Cell|October 4, 2002
Angiopoietin-2 is required for postnatal angiogenesis and lymphatic patterning, and only the latter role is rescued by Angiopoietin-1Nicholas W Gale, Gavin Thurston, Sean F Hackett, et al.
The Journal of Clinical Investigation|August 14, 2019
AAV8-vectored suprachoroidal gene transfer produces widespread ocular transgene expressionKun Ding, Jikui Shen, Zibran Hafiz, et al.
Biomaterials|March 16, 2020
Sustained delivery of acriflavine from the suprachoroidal space provides long term suppression of choroidal neovascularizationSean F Hackett, Jie Fu, Yoo Chun Kim, et al.
Investigative Ophthalmology & Visual Science|August 27, 2005
Suppression and regression of choroidal neovascularization by polyamine analoguesRaquel Lima e Silva, Yoshitsugu Saishin, Yumiko Saishin, et al.
FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology|May 25, 2007
The SDF-1/CXCR4 ligand/receptor pair is an important contributor to several types of ocular neovascularizationRaquel Lima e Silva, Jikui Shen, Sean F Hackett, et al.
FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology|April 2, 2005
Different effects of angiopoietin-2 in different vascular beds: new vessels are most sensitiveYuji Oshima, Sachiko Oshima, Hiroyuki Nambu, et al.
The Journal of Clinical Investigation|September 3, 2014
Targeting VE-PTP activates TIE2 and stabilizes the ocular vasculatureJikui Shen, Maike Frye, Bonnie L Lee, et al.
Nature Biomedical Engineering|September 8, 2020
Gelling hypotonic polymer solution for extended topical drug delivery to the eyeYoo Chun Kim, Matthew D Shin, Sean F Hackett, et al.
Mabs|December 9, 2016
Generation and characterization of ABBV642, a dual variable domain immunoglobulin molecule (DVD-Ig) that potently neutralizes VEGF and PDGF-BB and is designed for the treatment of exudative age-related macular degenerationKun Ding, Lucia Eaton, Diana Bowley, et al.
Pageof 5

Showing results (41-50 of 49) with videos related to

Sort By:
Pageof 5
You have reached the last page of results.This site can display upto 49 results.
Developmental Cell|October 4, 2002
Angiopoietin-2 is required for postnatal angiogenesis and lymphatic patterning, and only the latter role is rescued by Angiopoietin-1Nicholas W Gale, Gavin Thurston, Sean F Hackett, et al.
The Journal of Clinical Investigation|August 14, 2019
AAV8-vectored suprachoroidal gene transfer produces widespread ocular transgene expressionKun Ding, Jikui Shen, Zibran Hafiz, et al.
Biomaterials|March 16, 2020
Sustained delivery of acriflavine from the suprachoroidal space provides long term suppression of choroidal neovascularizationSean F Hackett, Jie Fu, Yoo Chun Kim, et al.
Investigative Ophthalmology & Visual Science|August 27, 2005
Suppression and regression of choroidal neovascularization by polyamine analoguesRaquel Lima e Silva, Yoshitsugu Saishin, Yumiko Saishin, et al.
FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology|May 25, 2007
The SDF-1/CXCR4 ligand/receptor pair is an important contributor to several types of ocular neovascularizationRaquel Lima e Silva, Jikui Shen, Sean F Hackett, et al.
FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology|April 2, 2005
Different effects of angiopoietin-2 in different vascular beds: new vessels are most sensitiveYuji Oshima, Sachiko Oshima, Hiroyuki Nambu, et al.
The Journal of Clinical Investigation|September 3, 2014
Targeting VE-PTP activates TIE2 and stabilizes the ocular vasculatureJikui Shen, Maike Frye, Bonnie L Lee, et al.
Nature Biomedical Engineering|September 8, 2020
Gelling hypotonic polymer solution for extended topical drug delivery to the eyeYoo Chun Kim, Matthew D Shin, Sean F Hackett, et al.
Mabs|December 9, 2016
Generation and characterization of ABBV642, a dual variable domain immunoglobulin molecule (DVD-Ig) that potently neutralizes VEGF and PDGF-BB and is designed for the treatment of exudative age-related macular degenerationKun Ding, Lucia Eaton, Diana Bowley, et al.
Pageof 5